Scholar Rock Holding

Executive Summary

Scholar Rock Holding (NASDAQ: SRRK) is a clinical-stage biopharmaceutical company developing selective inhibitors of growth factor activation, primarily targeting the TGFβ superfamily. Its lead asset, apitegromab, is a myostatin inhibitor in late-stage development for spinal muscular atrophy (SMA), with a completed Phase 3 trial (NCT05156320) and an ongoing Phase 3 (NCT05626855) expected to support regulatory filings. The company is also advancing apitegromab into facioscapulohumeral muscular dystrophy (FSHD) and obesity, leveraging a combination with tirzepatide. Additional pipeline includes SRK-181 (anti-latent TGFβ1) in oncology and SRK-439 in preclinical. Scholar Rock's platform differentiates by targeting latent growth factors, potentially improving therapeutic indices. Key near-term drivers include data readouts from its obesity combination trial and progress in SMA and FSHD.

Upcoming Catalysts (preview)

• Q3 2026Apitegromab + Tirzepatide Obesity Phase 2 Topline Data50% success
• Q2 2027Apitegromab FSHD Phase 2 (NCT07435129) Enrollment Completion & Interim Efficacy40% success
• Q4 2027Apitegromab SMA Phase 3 (NCT05626855) Interim Analysis70% success